Evidence map›Paper›PMID 29208425›Full record

ArticleInternational journal of cardiology2018

Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study.

S Goya Wannamethee, Olia Papacosta, Lucy Lennon, Peter H Whincup

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease.International journal of cardiology. Heart & vasculature · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Retrospective Study from a Single Center to Evaluate the Association Between Sex and Serum Uric Acid Levels in 950 Patients with Atrial Fibrillation.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  9. Serum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Uric acid and cardiometabolic diseases.Clinical hypertension · 2020
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

S Goya WannametheeUCL Department of Primary Care & Population Health, UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK. Electronic address: g.wannamethee@ucl.ac.uk.
Olia PapacostaUCL Department of Primary Care & Population Health, UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK.
Lucy LennonUCL Department of Primary Care & Population Health, UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK.
Peter H WhincupPopulation Health Research Institute, St George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
University College London · GBRoland Hill (United Kingdom) · GBSt George's, University of London · GB

Funding

British Heart Foundation RG/13/16/30528
6 · The paper itself

Abstract

The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain. We have prospectively examined the relationship between SUA and incident HF in 3440 men aged 60-79years separately in those on and not on antihypertensive treatment who were followed up for a mean period of 15years. Men on SUA lowering drugs and those with history of HF or myocardial infarction were excluded. There were 260 incident HF cases. The men were divided into three groups of SUA concentrations/levels (<350, 350-410 and >410μmol/L). Raised SUA was associated with significantly increased risk of HF in men on antihypertensive treatment (N=949) but not in those without (N=2491) (p=0.003 for interaction). In men on antihypertensive treatment those with hyperuricemia (>410μmol/L) had the most adverse biological risk profile for HF including the highest rates of atrial fibrillation and renal dysfunction and the highest mean level of BMI, c-reactive protein and cardiac function (cardiac troponin T). Treated hypertensive men with SUA levels>410μmol/L showed an increase in risk of HF of more than twofold compared to those on treatment with levels <350μmol/L even after adjustment for lifestyle characteristics and biological risk factors [adjusted hazard ratio 2.26 (1.23,4.15)]. SUA improved prediction of HF beyond routine conventional risk factors (p=0.02 for improvement in c-statistics). SUA as a marker of increased xanthine oxidase activity may be a useful prognostic marker for HF risk in older men on antihypertensive treatment.

Indexed as

AgedAntihypertensive AgentsBiomarkersCohort StudiesEnglandFollow-Up StudiesHeart FailureHumansHypertensionHyperuricemiaMaleMiddle AgedProspective StudiesRisk FactorsTreatment OutcomeUric AcidAntihypertensive AgentsBiomarkersUric AcidEpidemiologyHeart failureHypertensionSerum uric acid

Identifiers

PMID29208425
PMCPMC5766825
OpenAlexW2770508840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.